Healios (TYO:4593) will seek conditional approval in Japan for MultiStem to treat acute respiratory distress syndrome, following successful Phase 2 studies in Japan, the US, and the UK, according to its filing on Wednesday.
This decision eliminates the need for a planned Phase 3 trial in Japan, originally intended as a confirmatory study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments